Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavorable outcomes

Neuro-Oncology

Volumn 13, Issue 2, 2011, Pages 176-183

  Senetta, Rebecca ^a   Miracco, Clelia ^b   Lanzafame, Salvatore ^c   Chiusa, Luigi ^a   Caltabiano, Rosario ^c   Galia, Antonio ^d   Stella, Giulia ^e   Cassoni, Paola ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d CANNIZZARO HOSPITAL   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Caveolin 1; EGFR; Ependymomas; IHC; Survival

Indexed keywords

CAVEOLIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; PROTEIN P53;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EPENDYMOMA; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SURVIVAL RATE; UNIVARIATE ANALYSIS; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; CAVEOLIN 1; DNA, NEOPLASM; EPENDYMOMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; POINT MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUPRATENTORIAL NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 79951847980     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq160     Document Type: Article

References (45)

1. Palm T, Figarella-Branger D, Chapon F, et al. Expression profiling of ependymomas unravels localization and tumor grade-specific tumori-genesis. Cancer. 2009;115:3955-3968.
2. Metellus P, Figarella-Branger D, Guyotat J, et al. Supratentorial ependy-momas: prognostic factors and outcome analysis in a retrospective series of 46 adult patients. Cancer. 2008;113:175-185. (Pubitemid 351976399)
3. McLendon RE, Wiestler OD, Kros JM, Korshunov A, Ng HK. Ependymal tumors. In: Louis, DN, Ohgaki, H, Wiestler, OD, Cavenee, WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyons: IARC Press; 2007:69-79.
4. Chiu JK, Woo SY, Ater J, et al. Intracranial ependymoma in children: analysis of prognostic factors. J Neurooncol. 1992;13:283-290.
5. Ernestus RI, Schroder R, Stutzer H, Klug N. The clinical and prognostic relevance of grading in intracranial ependymomas. Br J Neurosurg. 1997;11:421-428. (Pubitemid 27440260)
6. Figarella-Branger D, Civatte M, Bouvier-Labit C, et al. Prognostic factors in intracranial ependymomas in children. J Neurosurg. 2000;93:605-613. (Pubitemid 32799294)
7. Ho DM, Hsu CY, Wong TT, Chiang H. A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for ana-plastic ependymoma. J Neurooncol. 2001;54:77-85. (Pubitemid 33089263)
8. Nazar GB, Hoffman HJ, Becker LE, Jenkin D, Humphreys RP, Hendrick EB. Infratentorial ependymomas in childhood: prognostic factors and treatment. J Neurosurg. 1990;72:408-417. (Pubitemid 20072964)
9. Zamecnik J, Snuderl M, Eckschlager T. Pediatric intracranial ependymo-mas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Mod Pathol. 2003;6:980-991. (Pubitemid 37280813)
10. Kuncova K, Janda A, Kasal P, Zamecnik J. Immunohistochemical prognostic markers in intracranial ependymomas: systematic review and meta-analysis [published online ahead of print]. Pathol Oncol Res. 2009;15:604-615.
11. Massimino M, Buttarelli FR, Antonelli M, Gandola L, Modena P, Giangaspero F. Intracranial ependymoma: factors affecting outcome. Future Oncol. 2009;5:207-216.
12. Korshunov A, Golanov A, Timirgaz V. Immunohistochemical markers for prognosis of ependymal neoplasms. J Neurooncol. 2002;58:255-270. (Pubitemid 34830636)
13. Kurt E, Zheng PP, Hop WC, et al. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. Cancer. 2006;106:388-395. (Pubitemid 43100449)
14. Prayson RA. Clinicopathologic study of 61 patients with ependymoma including MIB-1 immunohistochemistry. Ann Diagn Pathol. 1999;3:11-18.
15. Rickert CH, Paulus W. Prognosis-related histomorphological and immu-nohistochemical markers in central nervous system tumors of childhood and adolescence. Acta Neuropathol (Berl). 2005;109:69-92. (Pubitemid 40287791)
16. Ritter AM, Hess KR, McLendon RE, Langford LA. Ependymomas: MIB-1 proliferation index and survival. J Neurooncol. 1998;40:51-57. (Pubitemid 28548372)
17. Rushing EJ, Brown DF, Hladik CL, Risser RC, Mickey BE, White CL. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype. Mod Pathol. 1998;11:464-470. (Pubitemid 28224449)
18. Shuangshoti S, Rushing EJ, Mena H, Olsen C, Sandberg GD. Supratentorial extraventricular ependymal neoplasms: a clinicopatholo-gic study of 32 patients. Cancer. 2005;103:2598-2605. (Pubitemid 40800540)
19. Suri VS, Tatke M, Singh D, Sharma A. Histological spectrum of ependymomas and correlation of p53 and Ki-67 expression with ependymoma grade and subtype. Indian J Cancer. 2004;41:66-71. (Pubitemid 39164005)
20. Suzuki S, Oka H, Kawano N, Tanaka S, Utsuki S, Fujii K. Prognostic value of Ki-67 (MIB-1) and p53 in ependymomas. Brain Tumor Pathol. 2001;18:151-154.
21. Mendrzyk F, Korshunov A, Benner A, et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res. 2006;12:2070-2079.
22. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157-173. (Pubitemid 43357943)
23. Godard S, Getz G, Delorenzi M, et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 2003;63:6613-6625. (Pubitemid 37322939)
24. Nigro JM, Misra A, Zhang L, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 2005;65:1678-1686. (Pubitemid 40478592)
25. Cassoni P, Senetta R, Castellano I, et al. Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendro-gliomas: concrete premises for a new reliable diagnostic marker in gliomas. Am J Surg Pathol. 2007;31:760-769. (Pubitemid 46684217)
26. Senetta R, Trevisan E, Rudà R, et al. Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas. J Neuropathol Exp Neurol. 2009;68:425-431.
27. Burgermeister E, Liscovitch M, Röcken C, Schmid RM, Ebert MP. Caveats of caveolin-1 in cancer progression. Cancer Lett. 2008;268:187-201.
28. Goetz JG, Lajoie P, Wiseman SM, Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev. 2008;27:715-735.
29. Williams TM, Sotgia F, Lee H, et al. Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. Am J Pathol. 2006;169:1784-1801. (Pubitemid 351182008)
30. Bonuccelli G, Casimiro MC, Sotgia F, et al. Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature. Am J Pathol. 2009;174:1650-1662.
31. Abulrob A, Giuseppin S, Andrade MF, McDermid A, Moreno M, Stanimirovic D. Interactions of EGFR and caveolin-1 in human glioblas-toma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene. 2004;23:6967-6979. (Pubitemid 39279997)
32. Merz JF, Sankar P, Taube SE, Li Volsi VA. Use of human tissues in research: clarifying clinician and researcher roles and information flows. J Invest Med. 1997;45:252-257. (Pubitemid 127454836)
33. Li T, Sotgia F, Vuolo MA, et al. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am J Pathol. 2006;168:1998-201.
34. Cox D. Regressionsmodels and life table. JR Stat. Soc. 1972;34:187-220.
35. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
36. Verstegen MJ, Leenstra DT, Ijlst-Keizers H, Bosch DA. Proliferation-and apoptosis-related proteins in intracranial ependymomas: an immunohis-tochemical analysis. J Neurooncol. 2002;56:21-28. (Pubitemid 34256614)
37. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol. 1998;153:141-148. (Pubitemid 28317516)
38. Barresi V, Buttarelli FR, Vitarelli EE, Arcella A, Antonelli M, Giangaspero F. Caveolin-1 expression in diffuse gliomas: correlation with the proliferation index, epidermal growth factor receptor, p53, and 1p/19q status. Hum Pathol. 2009;40:1738-1746.
39. Agelaki S, Spiliotaki M, Markomanolaki H, et al.. Caveolin-1 regulates EGFR signalling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Cancer Biol Ther. 2009;8:1470-1477.
40. Khan EM, Heidinger JM, Levy M, Lisanti MP, Ravid T, Goldkorn T. Epidermal growth factor receptor exposed to oxidative stress undergoes Src-and caveolin-1-dependent perinuclear trafficking. J Biol Chem. 2006;281:14486-14493. (Pubitemid 43848379)
41. Dittmann K, Mayer C, Kehlbach R, Rodemann HP. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer. 2008;7:69.
42. Huang F, Reeves K, Han X, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 2007;67:2226-2238. (Pubitemid 46424242)
43. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997;13:513-609. (Pubitemid 28034534)
44. Hirose Y, Aldape K, Bollen A, James CD, Brat D, Lamborn K, Berger M, Feuerstein BG. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol. 2001;158:1137-1143. (Pubitemid 32221806)
45. Lefranc F, Rynkowski M, De Witte O, Kiss R. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment. Adv Tech Stand Neurosurg. 2009;34:3-35.